small molecule

ZEPOSIA

OZANIMOD HYDROCHLORIDE

Loss of exclusivitySeptember 2038latest FDA-listed patent expiry

CompanyBRISTOL MYERS SQUIBB CO

Drug detail

Brand name	ZEPOSIA
Active ingredient	OZANIMOD HYDROCHLORIDE
Strength	EQ 0.23MG BASE
Dosage form	CAPSULE
Route	ORAL
Modality	Small molecule
FDA approval	March 2020
Marketing status	RX

Listed patents

Patent	Expires	Type
11680050	September 2038	substance, product
8481573	March 2033	substance, product
10239846	November 2030	use U-3740
9382217	May 2029	use U-2774
8796318	May 2029	substance, product

Regulatory exclusivity

Code	Expires
M-309	August 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from BRISTOL MYERS SQUIBB CO